Antiangiogenesis in haematological malignancies

Area of Science:

• Oncology
• Hematology
• Vascular Biology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for cancer progression and a therapeutic target.
• In hematological malignancies, angiogenesis occurs within the bone marrow's complex cellular microenvironment.
• Antiangiogenic agents disrupt nutrient supply and cellular interactions that sustain cancer growth.

Purpose of the Study:

• To review the role of angiogenesis in hematological malignancies.
• To discuss the clinical activity of antiangiogenic agents in blood cancers.
• To highlight vascular endothelial growth factor (VEGF) as a therapeutic target and predictive marker in leukemia.

Main Methods:

• Review of existing literature on angiogenesis inhibitors in hematological malignancies.
• Analysis of clinical data for agents like thalidomide, lenalidomide, bortezomib, and bevacizumab.
• Focus on the role of VEGF in leukemia pathogenesis and treatment.

Main Results:

• Several antiangiogenic agents have demonstrated clinical efficacy in myeloma, myelodysplastic syndrome, and leukemia.
• VEGF is identified as a significant target in leukemia, with potential as a predictive marker for relapse.
• Anti-VEGF strategies show potential for primary, sequential, or adjunctive treatment of leukemia.

Conclusions:

• Angiogenesis inhibition is a validated therapeutic strategy in hematological malignancies.
• Targeting VEGF offers a promising approach for leukemia treatment and monitoring.
• Further development of antiangiogenic strategies is warranted for blood cancers.